PRNewswire/ -- (NYSE: LLY), the maker of Zepbound (tirzepatide), today announced positive results from ATTAIN-OSA, a Phase 3 ...

No. 55 / 2026 Zealand Pharma announces Boehringer Ingelheim’s survodutide is the first glucagon/GLP-1 dual agonist to ...

Lilly plans to file by the end of the year for U.S. approval of the daily pill for moderate-to-severe obstructive sleep apnea ...

Millions of sleep apnoea sufferers could one day ditch bulky breathing machines in favour of a daily weight loss pill.

Never say we don’t cater for all tastes with Glossy Picks. This week: what Kimberley Walsh did next, clever patches to plump ...

Eli Lilly advances Foundayo for sleep apnea after successful late-stage trial data in obese adults. U.S. approval is planned ...